Testosterone treatment comes of age: new options for hypogonadal men (Q28258718)

Testosterone replacement therapy: current trends and future directions

Europe PubMed Central

title

Testosterone treatment comes of age: new options for hypogonadal men (English)

0 references

1 reference

1 reference

Eberhard Nieschlag

1

0 references

language of work or name

English

0 references

publication date

September 2006

0 references

published in

Clinical Endocrinology

0 references

volume

65

0 references

page(s)

275-81

0 references

issue

3

0 references

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2265.2006.02618.X

On crystalline male hormone from testicles (testosterone) effective as from urine or from cholesterol

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Über Testosteron. Umwandlung des Dehydro-androsterons in Androstendiol und Testosteron; ein Weg zur Darstellung des Testosterons aus Cholesterin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Sexualhormone VII. Über die künstliche Herstellung des Testikelhormons Testosteron (Androsten-3-on-17-ol)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Blood testosterone threshold for androgen deficiency symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

An analysis of testosterone implants for androgen replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Potential adverse effects of long-term testosterone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

A Clinical Trial of 7α-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Urine testing for designer steroids by liquid chromatography with androgen bioassay detection and electrospray quadrupole time-of-flight mass spectrometry identification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Important effect of food on the bioavailability of oral testosterone undecanoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Development of methods of male contraception: impact of the World Health Organization Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Experience with transdermal testosterone replacement therapy for hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Progress towards hormonal male contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Reversible, non-barrier male contraception: status and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Estrogen plus progestin and the risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Risks of testosterone-replacement therapy and recommendations for monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Androgen receptor CAG repeat polymorphism is associated with fat-free mass in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Androgen receptor CAGn repeat length influences phenotype of 47,XXY (Klinefelter) syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X

Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02618.X